Edition:
United Kingdom

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

77.84USD
7:19pm GMT
Change (% chg)

$-0.10 (-0.13%)
Prev Close
$77.94
Open
$78.34
Day's High
$79.62
Day's Low
$77.14
Volume
45,331
Avg. Vol
212,154
52-wk High
$82.06
52-wk Low
$20.39

Latest Key Developments (Source: Significant Developments)

Esperion Therapeutics Q3 loss per share $1.86‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Esperion Therapeutics Inc :Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results.Expects full-year 2017 net cash used in operating activities to be approximately $135 million​.Expects cash and cash equivalents and investment securities to be approximately $272 million at December 31.Estimates cash resources are sufficient to fund operations through Q1 2020​.Qtrly loss per share $1.86‍​.Q3 earnings per share view $-1.78 -- Thomson Reuters I/B/E/S.  Full Article

Esperion announces initiation of pivotal late stage study for bempedoic acid
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Esperion Therapeutics Inc :Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill.Esperion Therapeutics - ‍NDA submission for LDL-C lowering indication for bempedoic acid / ezetimibe combination pill expected by Q1 2019​.Esperion Therapeutics Inc - ‍top-line results expected by q4 of 2018 for bempedoic acid / ezetimibe combination pill​.  Full Article

Meditor Group Ltd reports 8.2 pct passive stake in Esperion Therapeutics Inc
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Esperion Therapeutics Inc ::Meditor Group Ltd reports 8.2 percent passive stake in Esperion Therapeutics Inc as on Aug 10 - SEC filing​.  Full Article

BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics
Tuesday, 27 Sep 2016 

Esperion Therapeutics Inc :BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing.  Full Article

Esperion Therapeutics reports Q2 net loss of $14 mln
Thursday, 4 Aug 2016 

Esperion Therapeutics Inc : Estimates current cash resources are sufficient to fund operations into 2019 . Esperion Therapeutics provides bempedoic acid development program updates; reports second quarter 2016 financial results . Esperion had a net loss of $14.0 million for q2 of 2016 compared to $12.4 million .Esperion expects full-year 2016 net cash used in operating activities in 2016 will be approximately $65 to $75 million.  Full Article

Esperion Therapeutics provides regulatory update for Bempedoic Acid
Tuesday, 28 Jun 2016 

Esperion Therapeutics Inc : Esperion Therapeutics Inc says intends to initiate planned CVOT in statin intolerant patients who are at high risk for CV disease in Q4 of 2016 . Esperion expects full-year 2016 net cash used in operating activities to be between $65 to $75 million . Expects full-year 2016 cash and cash equivalents and investment securities to be approximately $220 million at December 31, 2016 . Current cash resources are expected to be sufficient to fund operations into early 2019 .Esperion Therapeutics provides clinical development and regulatory update for bempedoic acid.  Full Article

BRIEF-Esperion Reports Qtrly Loss Per Share $1.44

* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS